Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
The news feed for Sonnet BioTherapeutics Holdings, Inc. (formerly Nasdaq: SONN) provides an archive of company announcements, clinical updates, financing disclosures, and corporate transaction news. Sonnet is described as an oncology-focused biotechnology company that develops targeted biologic drugs using its proprietary FHAB (Fully Human Albumin Binding) platform, and its news releases highlight both scientific progress and significant strategic developments.
Readers can review detailed updates on Sonnet’s lead program, SON-1010 (IL‑12‑FHAB), including Phase 1b/2a trial data from the SB221 study in advanced solid tumors and platinum-resistant ovarian cancer. Company news has discussed dose-escalation results, safety and tolerability findings, partial responses observed at higher dose levels, and plans for expansion cohorts and randomized proof-of-concept stages. Additional releases cover SON-1210, an IL12-FHAB-IL15 construct for solid tumors, and collaborations such as those with Roche and the Sarcoma Oncology Center.
The news archive also documents Sonnet’s participation in industry conferences, virtual investor events, and educational segments where members of management and clinical leadership discuss trial design, safety data, and the scientific rationale behind the FHAB platform. These communications offer context on how Sonnet approaches issues like cytokine toxicity, therapeutic windows, and tumor microenvironment targeting.
A major theme in recent news is the business combination between Sonnet BioTherapeutics Holdings, Inc., Hyperliquid Strategies Inc., and Rorschach I LLC. Press releases outline the terms of the transaction, the creation of Hyperliquid Strategies Inc. as a digital asset treasury company focused on the HYPE token, and the resulting structure in which Sonnet becomes a wholly owned subsidiary. These items explain that Hyperliquid Strategies Inc.’s common stock is expected to trade on Nasdaq under the ticker PURR and that Sonnet’s common stock will no longer trade separately.
By following this news stream, investors and observers can see how Sonnet’s clinical developments, financing activities, governance decisions, and corporate transformation have been communicated over time. The archive helps place individual announcements in the broader context of the company’s oncology pipeline and its integration into a parent entity focused on digital asset treasury management.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced positive results from a preclinical GLP repeat-dose study of SON-1010, a proprietary Interleukin 12 biologic, in nonhuman primates. The No Observed Adverse Event Level was over 50 times the expected human dose, with no cytokine release syndrome noted. The pharmacokinetic profile showed a half-life of approximately 40 hours, enhancing therapeutic potential. Additionally, significant increases in Interferon-γ, an anti-tumor cytokine, were recorded. These findings support the safety and efficacy of SON-1010 for future clinical trials.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has signed a licensing agreement with New Life Therapeutics (NLT) for low-dose Interleukin 6 to treat Diabetic Peripheral Neuropathy (DPN) in ASEAN countries. The deal includes an upfront payment of $1 million and up to $20 million in milestone payments, along with royalties of 12% to 30% on net sales. NLT will manage a Phase 1b/2a clinical trial, set to begin in the second half of 2021. This partnership aims to address rising diabetes rates in the region and bring innovation to neuropathy treatment.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) provided an update on its ongoing programs. The company has completed GLP toxicity studies for SON-1010 and SON-080, with plans to initiate clinical trials in the second half of 2021. A partnership with New Life Therapeutics for SON-081 aims to advance it into clinical trials. Sonnet is actively developing several candidates, including SON-1210 and SON-2014, with IND submissions planned. Additionally, the company received a Notice of Allowance for its FHAB delivery technology patent, strengthening its intellectual property portfolio.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has announced the appointments of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations, effective March 22, 2021. Dr. Kenney, with over 20 years of experience, will lead clinical development for Sonnet’s FHAB platform, aimed at treating challenging cancers. Dafonseca brings over 30 years of expertise in pharmaceutical development, recently managing oncology clinical operations at Merck. These strategic appointments come as the company prepares to advance its proprietary IL-12 therapeutic candidate, SON-1010, into clinical trials.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) provided a business update and financial results for Q1 FY 2021, reporting a cash balance of $2.3 million as of December 31, 2020. The company announced successful non-human primate studies for its lead therapeutic candidate, SON-1010, which demonstrated on-target activity and tolerability. Sonnet plans to file an IND for SON-1010 in the second half of 2021, alongside additional trials for SON-080 and SON-1210. The company has initiated an at-the-market offering program aiming to raise up to $15.9 million.
Summary not available.
Sonnet BioTherapeutics (NASDAQ:SONN) has completed a successful non-human primate study of SON-1010, a fully human Interleukin 12 (IL-12) therapeutic candidate. The study demonstrated SON-1010's improved pharmacokinetic profile compared to recombinant human IL-12 and confirmed its safety at doses significantly higher than expected for human trials. Key findings include a prolonged half-life of 40 hours for subcutaneous doses and potent pharmacodynamic effects indicated by increased Interferon-γ levels. These results pave the way for IND filing with the FDA and potential clinical trials targeting lung and head and neck cancers.
Sonnet BioTherapeutics announced positive results from a preclinical study of SON-1010, a human IL-12 candidate. The SCID mouse study showed no toxicity or adverse immune reactions, indicating a favorable safety profile. Notably, cytokine storm was absent, and the dosing demonstrated a dose-dependent response in activating the immune system. The company plans to submit an Investigational New Drug (IND) application in 2021 and aims to initiate first-in-human clinical studies in the latter half of the year, reinforcing its commitment to advancing oncology therapies.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the successful exercise of 3,300,066 Series A Warrants at $3.19 per share, generating $10.5 million in gross proceeds. CFO Jay Cross highlighted that the funds will support the company’s clinical pipeline. Following this exercise, there are no Series A Warrants remaining, with 2,308,663 Series B and 11,329,461 Series C Warrants still outstanding, which could potentially raise an additional $36.1 million if fully exercised. The total outstanding shares now total 14.7 million.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced successful completion of a warrant repricing, raising $10.5 million. The company is negotiating a potential licensing deal for its low-dose IL-6 asset, SON-081, for diabetic peripheral neuropathy, which could yield $40 million in upfront fees and milestone payments. In Q1 2020, Sonnet reported $3.1 million in cash and R&D expenses increased to $2.5 million, while administrative costs also rose. The firm expects to submit INDs for its assets in 2021 despite COVID-19 related delays.
FAQ
What is the current stock price of Sonnet Biotherapeutc Hldng (SONN)?
What is the market cap of Sonnet Biotherapeutc Hldng (SONN)?
